IRB #

STUDY00020518

Title

CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY

Principal Investigator

Rajan Kulkarni

Study Purpose

The purpose of the study is to determine, long term, how well the drug, cemiplimab, works in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).

Medical Condition(s)

Cutaneous Squamous Cell Carcinoma, CSCC

Eligibility Criteria

1. ≥18 years of age

2. Eligible for treatment with and prescribed cemiplimab for advanced CSCC in accordance with approved prescribing information

Healthy Volunteers Needed

No

Placebo Chance

N/A

Duration of Participation

36 months

Minors Included

No

Contact

Call our Dermatology clinical trials recruiter at 503-418-9386 or email dermtrials@ohsu.edu

Sponsor

Regeneron

Recruitment End

12/31/2021

Compensation Provided

No


Go Back